362 related articles for article (PubMed ID: 30030317)
1. Efficacy of oral administration of cystine and theanine in patients with colorectal cancer undergoing capecitabine-based adjuvant chemotherapy after surgery: study protocol for a multi-institutional, randomised, double-blinded, placebo-controlled, phase II trial.
Hamaguchi R; Tsuchiya T; Miyata G; Sato T; Takahashi K; Ariyoshi K; Oyamada S; Iwase S
BMJ Open; 2018 Jul; 8(7):e021442. PubMed ID: 30030317
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of oral administration of cystine and theanine in colorectal cancer patients undergoing capecitabine-based adjuvant chemotherapy after surgery: a multi-institutional, randomized, double-blinded, placebo-controlled, phase II trial (JORTC-CAM03).
Hamaguchi R; Tsuchiya T; Miyata G; Sato T; Takahashi K; Miura K; Oshio H; Ohori H; Ariyoshi K; Oyamada S; Iwase S
Support Care Cancer; 2020 Aug; 28(8):3649-3657. PubMed ID: 31811480
[TBL] [Abstract][Full Text] [Related]
3. Capecitabine versus S-1 as adjuvant chemotherapy for patients with stage III colorectal cancer (JCOG0910): an open-label, non-inferiority, randomised, phase 3, multicentre trial.
Hamaguchi T; Shimada Y; Mizusawa J; Kinugasa Y; Kanemitsu Y; Ohue M; Fujii S; Takiguchi N; Yatsuoka T; Takii Y; Ojima H; Masuko H; Kubo Y; Mishima H; Yamaguchi T; Bando H; Sato T; Kato T; Nakamura K; Fukuda H; Moriya Y
Lancet Gastroenterol Hepatol; 2018 Jan; 3(1):47-56. PubMed ID: 29079411
[TBL] [Abstract][Full Text] [Related]
4. Oral administration of the amino acids cystine and theanine attenuates the adverse events of S-1 adjuvant chemotherapy in gastrointestinal cancer patients.
Tsuchiya T; Honda H; Oikawa M; Kakita T; Oyama A; Oishi H; Tochikubo K; Hashimoto T; Kurihara S; Shibakusa T; Kayahara T
Int J Clin Oncol; 2016 Dec; 21(6):1085-1090. PubMed ID: 27306219
[TBL] [Abstract][Full Text] [Related]
5. Low-dose capecitabine adjuvant chemotherapy in elderly stage II/III colorectal cancer patients (LC-ACEC): study protocol for a randomized controlled trial.
He Y; Liu P; Zhang Y; Deng X; Meng W; Wei M; Yang T; Wang Z; Qiu M
Trials; 2015 May; 16():238. PubMed ID: 26021722
[TBL] [Abstract][Full Text] [Related]
6. Protective effect of the oral administration of cystine and theanine on oxaliplatin-induced peripheral neuropathy: a pilot randomized trial.
Kobayashi M; Sato R; Komura T; Ichikawa H; Hirashima T; Otake S; Akazawa N; Yazawa T; Abe T; Okada T; Kakita T; Oikawa M; Tsuchiya T
Int J Clin Oncol; 2020 Oct; 25(10):1814-1821. PubMed ID: 32594273
[TBL] [Abstract][Full Text] [Related]
7. Study protocol of a single-arm phase 2 study evaluating the preventive effect of topical hydrocortisone for capecitabine-induced hand-foot syndrome in colorectal cancer patients receiving adjuvant chemotherapy with capecitabine plus oxaliplatin (T-CRACC study).
Iimura Y; Furukawa N; Ishibashi M; Ahiko Y; Tanabe T; Aikou S; Shida D; Nojima M; Kuroda S; Boku N
BMC Gastroenterol; 2022 Jul; 22(1):341. PubMed ID: 35836104
[TBL] [Abstract][Full Text] [Related]
8. Preplanned safety analysis of the JFMC37-0801 trial: a randomized phase III study of six months versus twelve months of capecitabine as adjuvant chemotherapy for stage III colon cancer.
Suto T; Ishiguro M; Hamada C; Kunieda K; Masuko H; Kondo K; Ishida H; Nishimura G; Sasaki K; Morita T; Hazama S; Maeda K; Mishima H; Ike H; Sadahiro S; Sugihara K; Okajima M; Saji S; Sakamoto J; Tomita N
Int J Clin Oncol; 2017 Jun; 22(3):494-504. PubMed ID: 28078540
[TBL] [Abstract][Full Text] [Related]
9. [Oral capecitabine as postoperative adjuvant chemotherapy in stage III colon cancer patients].
Yamaguchi T; Fukuda M; Yasui H; Okazaki S; Kubo K; Tanaka M; Une Y; Setoguchi Y; Hanada K; Moriyama S; Tani M; Murakami T; Okuchi Y; Ogiso S; Hata H; Sakata S; Otani T; Yamato T; Ikai I
Gan To Kagaku Ryoho; 2012 Mar; 39(3):389-93. PubMed ID: 22421765
[TBL] [Abstract][Full Text] [Related]
10. Comparing the effectiveness of capecitabine versus 5-fluorouracil/leucovorin therapy for elderly Taiwanese stage III colorectal cancer patients based on quality-of-life measures (QLQ-C30 and QLQ-CR38) and a new cost assessment tool.
Lin JK; Tan EC; Yang MC
Health Qual Life Outcomes; 2015 May; 13():61. PubMed ID: 25986478
[TBL] [Abstract][Full Text] [Related]
11. Feasibility of sequential adjuvant chemotherapy with a 3-month oxaliplatin-based regimen followed by 3 months of capecitabine in patients with stage III and high-risk stage II colorectal cancer: JSWOG-C2 study.
Tsuruta A; Yamashita K; Tanioka H; Tsuji A; Inukai M; Yamakawa T; Yamatsuji T; Yoshimitsu M; Toyota K; Yamano T; Nagasaka T; Okajima M
Drug Des Devel Ther; 2016; 10():3827-3835. PubMed ID: 27920498
[TBL] [Abstract][Full Text] [Related]
12. [Capecitabine].
Yamaguchi K; Shimamura T; Tada M
Gan To Kagaku Ryoho; 2006 Jul; 33(7):891-5. PubMed ID: 16835474
[TBL] [Abstract][Full Text] [Related]
13. Protocol of a randomised phase III clinical trial of sequential capecitabine or 5-fluorouracil plus bevacizumab (Cape/5-FU-Bmab) to capecitabine or 5-fluorouracil plus oxaliplatin plus bevacizumab (CapeOX/mFOLFOX6-Bmab) versus combination CapeOX/mFOLFOX6-Bmab in advanced colorectal cancer: the C-cubed (C3) study.
Nagasaka T; Mishima H; Sawaki A; Shimokawa M; Inukai M; Shinozaki K; Tanioka H; Nasu J; Nishina T; Hazama S; Okajima M; Yamaguchi Y
BMJ Open; 2016 Jun; 6(6):e011454. PubMed ID: 27256093
[TBL] [Abstract][Full Text] [Related]
14. Predictors of Hand-Foot Syndrome and Pyridoxine for Prevention of Capecitabine-Induced Hand-Foot Syndrome: A Randomized Clinical Trial.
Yap YS; Kwok LL; Syn N; Chay WY; Chia JWK; Tham CK; Wong NS; Lo SK; Dent RA; Tan S; Mok ZY; Koh KX; Toh HC; Koo WH; Loh M; Ng RCH; Choo SP; Soong RCT
JAMA Oncol; 2017 Nov; 3(11):1538-1545. PubMed ID: 28715540
[TBL] [Abstract][Full Text] [Related]
15. Laparoscopic or open distal gastrectomy after neoadjuvant chemotherapy for advanced gastric cancer: study protocol for a randomised phase II trial.
Li Z; Shan F; Ying X; Zhang L; Ren H; Li S; Jia Y; Miao R; Xue K; Li Z; Wang Y; Yan C; Zhang Y; Pang F; Ji J
BMJ Open; 2018 Aug; 8(8):e021633. PubMed ID: 30099396
[TBL] [Abstract][Full Text] [Related]
16. The effect of TJ-28 (Eppikajutsuto) on the prevention of hand-foot syndrome using Capecitabine for colorectal cancer: The Yokohama Clinical Oncology Group Study (YCOG1102).
Watanabe K; Ishibe A; Watanabe J; Ota M; Fujii S; Ichikawa Y; Oba MS; Endo I
Indian J Gastroenterol; 2020 Apr; 39(2):204-210. PubMed ID: 32406009
[TBL] [Abstract][Full Text] [Related]
17. The effectiveness of EVOSKIN®Palm and sole moisturizing cream in treating capecitabine-associated hand-foot syndrome: a randomized double-blind clinical trial.
Lu W; Huang Z; Chen S; Lv H; Chen X; Lei J; Ke C; Hong C; Wei Y; Su R; Chen R; Sun Z; Yang P; Tan X; Liu H
Ann Palliat Med; 2021 Mar; 10(3):3009-3017. PubMed ID: 33849091
[TBL] [Abstract][Full Text] [Related]
18. Topical Diclofenac for Prevention of Capecitabine-Associated Hand-Foot Syndrome: A Double-Blind Randomized Controlled Trial.
Santhosh A; Sharma A; Bakhshi S; Kumar A; Sharma V; Malik PS; Pramanik R; Gogia A; Prasad CP; Sehgal T; Gund S; Dev A; Cheung WY; Pandey RM; Kumar S; Gupta I; Batra A;
J Clin Oncol; 2024 May; 42(15):1821-1829. PubMed ID: 38412399
[TBL] [Abstract][Full Text] [Related]
19. Randomized phase III trial of S-1 versus capecitabine in the first-line treatment of metastatic colorectal cancer: SALTO study by the Dutch Colorectal Cancer Group.
Kwakman JJM; Simkens LHJ; van Rooijen JM; van de Wouw AJ; Ten Tije AJ; Creemers GJM; Hendriks MP; Los M; van Alphen RJ; Polée MB; Muller EW; van der Velden AMT; van Voorthuizen T; Koopman M; Mol L; van Werkhoven E; Punt CJA
Ann Oncol; 2017 Jun; 28(6):1288-1293. PubMed ID: 28383633
[TBL] [Abstract][Full Text] [Related]
20. CapeOX perioperative chemotherapy versus postoperative chemotherapy for locally advanced resectable colon cancer: protocol for a two-period randomised controlled phase III trial.
Liu F; Tong T; Huang D; Yuan W; Li D; Lin J; Cai S; Xu Y; Chen W; Sun Y; Zhuang J
BMJ Open; 2019 Jan; 9(1):e017637. PubMed ID: 30700474
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
